Financial Conflicts of Interest – updated to include the 2011 revised FCOI regulation, promoting objectivity in research (42 CFR Part 50 Subpart F) NIH requires grantees and investigators to comply with the requirements of 42 CFR Part 50, Subpart F, “Responsibility of Applicants for Promoting Objectivity in Research for Which PHS Funding is sought.” That [...]
View PostLeung PY, Hurst S, Berny-Lang MA, Verbout NG, Gailani D, Tucker EI, Wang RK, McCarty OJT, Gruber A. Translational Stroke Research 2012. Epub 2012 May 3. Blood coagulation factor XI (FXI) is an established risk factor for acute ischemic stroke (AIS) and thrombosis, but is also needed for normal hemostasis. Contact factor XII (FXII), an [...]
View Post factor XI, hemostasis, Ischemia, Neuroprotection, thrombolysisTucker EI, Verbout NG, Leung PY, Hurst S, McCarty OJ, Gailani D, Gruber A. Blood. 2012 May 17;119(20):4762-8. Epub 2012 Mar 22. Severe bacterial sepsis often leads to a systemic procoagulant and proinflammatory condition that can manifest as disseminated intravascular coagulation, septic shock, and multiple organ failure. Because activation of the contact proteases factor XII (FXII), prekallikrein, and factor XI (FXI) can [...]
View PostLöwenberg EC, Meijers JC, Monia BP, Levi M. J Thromb Haemost. 2010 Nov;8(11):2349-57. doi: 10.1111/j.1538-7836.2010.04031.x. Coagulation factor (F)XI was first described as a member of the contact pathway of coagulation. However, the ‘classic’ theory of the extrinsic and intrinsic pathway has been revised and FXI was found to be activated by thrombin and to play a role in sustained [...]
View Post factor XI, thromboembolic, thrombosisPham M, Stoll G, Nieswandt B, Bendszus M, Kleinschnitz C. J Mol Med (Berl). 2012 Feb;90(2):119-26. Epub 2011 Sep 10. Ischemic stroke is a devastating disease which, in most cases, is caused by thrombotic occlusion of brain arteries. The molecular mechanisms involved in microvascular thrombus formation during focal cerebral ischemia are not well understood. As a consequence, the current antithrombotic [...]
View Post factor XII, fibrin, ischemic stroke, thromboembolismLuo D, Szaba FM, Kummer LW, Johnson LL, Tucker EI, Gruber A, Gailani D, Smiley ST. Infect Immun. 2012 Jan;80(1):91-9. Epub 2011 Oct 17. In mice infected sublethally with Listeria monocytogenes, fibrin is deposited at low levels within hepatic tissue, where it functions protectively by limiting bacterial growth and suppressing hemorrhagic pathology. Here we demonstrate that mice infected with lethal doses of L. [...]
View Post bacterial growth, coagulopathy, factor XI, fibrin, inflammation, listeria, listeriosisHe R, Chen D, He S. Thromb Res. 2011 Dec 22. [Epub ahead of print] Coagulation factor FXI (FXI), a plasma serine protease zymogen, has important roles in both intrinsic and extrinsic coagulation pathways and bridges the initiation and amplification phases of plasmatic hemostasis. Recent studies have provided new insight into the molecular structure and functional features of [...]
View Post antithrombotics, FXI, fXIIaVicente CP, Weiler H, Di Cera E,Tollefsen DM. Thromb Res. 2011 Dec 16. The thrombin mutant W215A/E217A (WE thrombin) has greatly reduced procoagulant activity, but it activates protein C in the presence of thrombomodulin and inhibits binding of platelet glycoprotein Ib to von Willebrand factor and collagen under flow conditions. Both thrombomodulin-dependent protein C activation [...]
View Post E217A, protein C activation, von Willebrand factor, W215A/E217A, WE-thrombinDi Cera E. Prog Mol Biol Transl Sci. 2011;99:145-84. Thrombosis is the most prevalent cause of fatal diseases in developed countries. An antithrombotic agent that can be administered to patients with severe acute thrombotic diseases without the risk of causing hemorrhage, as experienced with antithrombotic/thrombolytic therapy in the treatment of acute ischemic stroke or systemic anticoagulants [...]
View Post antithrombotic, ischemic stroke, protease-activated receptors, Protein C, protein C activation, thrombolytic therapy, thrombosisMüller F, Gailani D, Renné T. Curr Opin Hematol. 2011 Sep;18(5):349-55. Arterial and venous thrombosis are major causes of morbidity and mortality, and the incidence of thromboembolic diseases increases as a population ages. Thrombi are formed by activated platelets and fibrin. The latter is a product of the plasma coagulation system. Currently available anticoagulants such as heparins, vitamin [...]
View Post Anticoagulation, arterial thrombosis, factor Xa, fibrin, fibrin formation, hemostasis, Thrombin, thromboembolic, VENOUS THROMBOSIS